

USSN 10/646,308

Docket No. 3432-US-NP

## 2. Listing of the Claims

This listing of claims will replace all prior versions and listings of claims in the application:

1.-45. *(canceled)*

46. *(currently amended)* A method for reducing chronic cardiotoxicity caused by a by an anthracycline chemotherapeutic agent in a cancer patient ~~subject in need of such a treatment,~~ comprising administering to the patient ~~subject~~ a 4-1BB antagonist in an amount sufficient to reduce the cardiotoxicity, wherein the 4-1BB antagonist is selected from the group consisting of a soluble 4-1BB protein comprising amino acids 1-163 of SEQ ID NO: 18 that blocks or reduces the interaction of 4-1BB and 4-1BB-L, an antibody that specifically binds 4-1BB and blocks or reduces the interaction of 4-1BB and 4-1BB-L, and an antibody that specifically binds 4-1BB-L and blocks or reduces the interaction of 4-1BB and 4-1BB-L.

47. *(previously presented)* The method according to Claim 46, wherein the cardiotoxicity is cardiomyopathy.

48. *(cancelled)*

49. *(currently amended)* The method according to Claim ~~46~~48, wherein the anthracycline chemotherapeutic agent ~~drug~~ is doxorubicin.

50. *(canceled)*

51. *(previously presented)* The method of Claim 46, wherein said soluble 4-1BB protein is an Fc fusion protein.

52.-63. *(canceled)*

64. *(previously presented)* The method of Claim 46, wherein the soluble 4-1BB protein is an oligomer.

65-67. *(cancelled)*